Silexion Therapeutics Corp (SLXN) FinancialsSLXNSilexion Therapeutics Corp

Evaluating the bottom line, Silexion Therapeutics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -17021.95%, provide a clear picture of how effectively SLXN converts its operational activities into shareholder value.

In the context of the broader market, SLXN competes directly with industry leaders such as SILO and SBFM. With a market capitalization of $2.09M, it holds a significant position in the sector. When comparing efficiency, SLXN's gross margin of N/A stands against SILO's -14.77% and SBFM's 25.35%. Such benchmarking helps identify whether Silexion Therapeutics Corp is trading at a premium or discount relative to its financial performance.

Silexion has reported consistent net losses, with a Q2 2026 net income loss of $3.55 million, widening from a $2.50 million loss in the same quarter last year. The company has a negative gross profit, indicating it is not generating revenue to cover its costs. The current ratio is at 0.94, suggesting potential liquidity issues.